Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 29;14(8):e250252.
doi: 10.1530/EC-25-0252. Print 2025 Aug 1.

Association of increased serum I-309 with renal function impairment and diabetic kidney disease in type 2 diabetes mellitus

Bing Zhao  1 , Miaomiao Zhang  1 , Zhiyu Zhang  2 , Yan Liang  3 , Zaixing Yang  1
Affiliations

Association of increased serum I-309 with renal function impairment and diabetic kidney disease in type 2 diabetes mellitus

Bing Zhao et al. Endocr Connect. .

Abstract

Objective: The aim of this study was to determine serum I-309 levels in type 2 diabetes mellitus (T2DM) patients, as well as the association with clinical/laboratory phenotypes and disease complications.

Methods: A total of 155 T2DM patients and 30 healthy controls (HC) were enrolled. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-10, IL-12, IL-17, IL-23, tumor necrosis factor-α (TNF-α), and interferon (IFN)-γ were measured. The relationships between I-309 and various clinical and laboratory variables were analyzed.

Results: The serum concentrations of I-309 were significantly higher in T2DM patients than in HC (P < 0.001). The serum I-309 levels were significantly elevated in T2DM patients with diabetic kidney disease (DKD), hypertension, coronary artery disease, peripheral neuropathy, peripheral artery disease, and diabetic ketosis (all P < 0.05), but reduced in drinkers (P = 0.018). The Spearman analysis showed that serum I-309 correlated positively with age, disease duration, CKD stages, urea, creatinine, urinary albumin-to-creatinine ratio, C-reactive protein, red blood cell distribution width, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, IL-6, IL-12, and IFN-γ, but negatively with estimated glomerular filtration rate (eGFR), fasting blood glucose, total bilirubin, albumin, lymphocyte count, red blood cell count, and hemoglobin. The multiple linear regression analysis indicated that serum I-309 was independently correlated only with eGFR and IFN-γ. The multivariate logistic regression analysis demonstrated that serum I-30 and IL-17A remained independently associated with DKD.

Conclusion: Serum I-309 is markedly elevated in T2DM patients and is associated with increased DKD risk, suggesting its potential role as both a promising biomarker and a pathogenic mediator in the progression of T2DM, particularly DKD.

Keywords: I-309; diabetic kidney disease; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the work reported.

Figures

Figure 1
Figure 1
Serum levels of I-309 in T2DM patients and HC.
Figure 2
Figure 2
The ROC analysis for diagnostic performance of serum I-309 for T2DM.
Figure 3
Figure 3
The ROC analysis for identification of DKD in T2DM patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Salunkhe VA, Veluthakal R, Kahn SE, et al. Novel approaches to restore beta cell function in prediabetes and type 2 diabetes. Diabetologia 2018. 61 1895–1901. ( 10.1007/s00125-018-4658-3) - DOI - PMC - PubMed
    1. Accili D, Deng Z & Liu Q. Insulin resistance in type 2 diabetes mellitus. Nat Rev Endocrinol 2025. 21 413–426. ( 10.1038/s41574-025-01114-y) - DOI - PubMed
    1. Guan J, Abudouaini H, Lin K, et al. Emerging insights into the role of IL-1 inhibitors and colchicine for inflammation control in type 2 diabetes. Diabetol Metab Syndr 2024. 16 140. ( 10.1186/s13098-024-01369-x) - DOI - PMC - PubMed
    1. Weinberg SR, Segev O, Dor S, et al. Overview of oxidative stress and inflammation in diabetes. J Diabetes 2024. 16 e70014. ( 10.1111/1753-0407.70014) - DOI - PMC - PubMed
    1. Oda Y, Nishi H & Nangaku M. Role of inflammation in progression of chronic kidney disease in type 2 diabetes mellitus: clinical implications. Semin Nephrol 2023. 43 151431. ( 10.1016/j.semnephrol.2023.151431) - DOI - PubMed

LinkOut - more resources